07:00 , Mar 31, 2014 |  BioCentury  |  Emerging Company Profile

ImmuSmol: Going small

Cancer cells can evade host immunity by up-regulating enzymes that produce small molecule metabolites capable of blocking T cells in the tumor microenvironment. ImmuSmol S.A.S. 's antibodies target the metabolites to restore the immune response...
07:00 , Oct 23, 2000 |  BC Week In Review  |  Company News

Biokeys Inc., BioQuest deal

The companies completed their previously announced merger (see BioCentury, May 30). BQST underwent a 1-for-1.9899 reverse split on July 26 resulting in 7 million shares outstanding. BQST then issued 7 million shares in exchange for...
07:00 , Aug 7, 2000 |  BC Week In Review  |  Clinical News

EradicAide HIV vaccine regulatory update

The University of Texas received European Patent No. 0671947 covering antiviral vaccines that elicit cytotoxic T lymphocyte (CTL) responses without eliciting an antibody response. BQST, the exclusive licensee of the patent, is developing its EradicAide...
07:00 , May 30, 2000 |  BC Week In Review  |  Company News

Biokeys Inc., BioQuest deal

The companies signed a definitive merger agreement subject to shareholder approval (see BioCentury, Feb. 28). Under the agreement, HIVX shares will undergo a 1-for-1.77 reverse stock split resulting in 7 million shares outstanding. HIV will...
07:00 , Apr 17, 2000 |  BC Week In Review  |  Company News

BioQuest, Biovector deal

The companies will evaluate the development of an HIV vaccine that combines HIVX's cocktail of HIV protein envelope peptides with Biovector's technology for delivering antigens in lipopeptide constructs to induce cellular immune responses. HIVX is...
08:00 , Feb 28, 2000 |  BC Week In Review  |  Company News

BioKeys Inc., BioQuest deal

The companies signed a letter of intent to merge, retaining the BioKeys name. BioKeys' Co-factor, which enhances treatment with 5-fluorouracil (5-FU) in colorectal and breast cancer, is about to begin Phase III testing. The company...
08:00 , Feb 16, 1999 |  BC Week In Review  |  Company News

BioQuest board of directors update

BioQuest Inc. (HIVX), Houston, Texas   Business: Infectious diseases   Appointed: R. Wayne Fritzsche, president of Fritzsche and Associates, as special advisor to the board of directors  ...
07:00 , Aug 10, 1998 |  BC Week In Review  |  Company News

BioQuest, Genetic Vectors deal

GVEC agreed in principle to acquire BioQuest, which provides biotechnology product development services. BioQuest Inc., Miami, Fla.   Genetic Vectors Inc. (GVEC), Miami, Fla.   Business: Gene/Cell therapy, Supply/Service  ...
07:00 , Jun 15, 1998 |  BC Week In Review  |  Company News

BioQuest, Immune Complex deal

HIVX signed agreements with original shareholders of Immune Complex, an HIVX subsidiary, to reduce to 20 percent from a majority shareholder position HIVX’s holdings in Immune Complex. HIVX will receive an undisclosed amount of cash...
07:00 , Jun 15, 1998 |  BC Week In Review  |  Company News

Immune Complex management update

(BioQuest reduces stake in Immune Complex, B3) Immune Complex Corp., San Diego, Calif.   Business: Infectious diseases   Transition: Louis Reif becomes CEO while remaining chairman, replacing George Thornton, formerly CEO, who remains CEO of...